Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals in India and internationally. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides fi...
Supriya Lifescience reported revenue of 6.96 billion INR for fiscal year 2025, up 22.1% from fiscal year 2024, and net income of 1.88 billion INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 2.06 billion INR, up 11.2% from a year before. Export was its largest region in fiscal year 2025, with 85% of revenue. Its market capitalization was 68.22 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
No profile data available.